These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35588936)

  • 1. Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research.
    Khaldoyanidi SK; Hindoyan A; Stein A; Subklewe M
    Crit Rev Oncol Hematol; 2022 Jul; 175():103710. PubMed ID: 35588936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
    Marchand T; Pinho S
    Front Immunol; 2021; 12():775128. PubMed ID: 34721441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.
    Costa RGA; Silva SLR; Dias IRSB; Oliveira MS; Rodrigues ACBDC; Dias RB; Bezerra DP
    Redox Biol; 2023 Jun; 62():102692. PubMed ID: 37031536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
    Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
    Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extinguishing the Embers: Targeting AML Metabolism.
    Culp-Hill R; D'Alessandro A; Pietras EM
    Trends Mol Med; 2021 Apr; 27(4):332-344. PubMed ID: 33121874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Lipid Metabolic Signatures in Acute Myeloid Leukemia.
    Singh P; Murali R; Shanmugam SG; Thomas S; Scott J; Warrier S; Arfuso F; Dharmarajan A; Gandhirajan RK
    Stem Cells; 2024 Mar; 42(3):200-215. PubMed ID: 38167958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.
    Thakral D; Gupta R; Khan A
    Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New approaches to target leukemia stem cells].
    Takenaka K; Akashi K
    Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell signaling pathways as molecular targets to eliminate AML stem cells.
    Rodrigues ACBDC; Costa RGA; Silva SLR; Dias IRSB; Dias RB; Bezerra DP
    Crit Rev Oncol Hematol; 2021 Apr; 160():103277. PubMed ID: 33716201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.
    Reinisch A; Chan SM; Thomas D; Majeti R
    Semin Hematol; 2015 Jul; 52(3):150-64. PubMed ID: 26111462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia: therapeutic targeting of stem cells.
    Pabon CM; Abbas HA; Konopleva M
    Expert Opin Ther Targets; 2022 Jun; 26(6):547-556. PubMed ID: 35634856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
    Brunetti M; Iasenza IA; Jenner AL; Raynal NJ; Eppert K; Craig M
    Leuk Res; 2024 May; 140():107485. PubMed ID: 38579483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.
    Carter JL; Hege K; Kalpage HA; Edwards H; Hüttemann M; Taub JW; Ge Y
    Biochem Pharmacol; 2020 Dec; 182():114253. PubMed ID: 33011159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
    Pelosi E; Castelli G; Testa U
    Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.